B-cell chronic lymphocytic leukemia (CLL) is characterized by slow accumulation of malignant cells, which are supported in the microenvironment by cell-cell interactions and soluble cytokines such as tumor necrosis factor (TNF). We evaluated the effect of the small molecule TNF inhibitor LMP-420 on primary CLL cells. The mean concentration of LMP-420 required to induce 50% cytotoxicity (ED50) at 72 h was 245 nM. LMP-420-induced time-and dose-dependent apoptosis, as shown by annexin V staining, caspase activation and DNA fragmentation. These changes were associated with decreased expression of anti-apoptotic proteins Mcl-1, Bcl-xL and Bcl-2. CLL cells from patients with poor prognostic indicators showed LMP-420 sensitivity equal to that for cells from patients with favorable characteristics. In addition, LMP-420 potentiated the cytotoxic effect of fludarabine and inhibited in vitro proliferation of stimulated CLL cells. Gene expression profiling indicated that the mechanism of action of LMP-420 may involve suppression of nuclear factor-jB and immune response pathways in CLL cells. LMP-420 had minimal effects on normal peripheral blood mononuclear cell, B-and T-cell function, and hematopoietic colony formation. Our data suggest that LMP-420 may be a useful treatment for CLL with negligible hematologic toxicities.
Introduction
Chronic lymphocytic leukemia (CLL) is an incurable and common adult B-cell malignancy. Although highly effective chemo-immunotherapy regimens exist for the first-line setting, treatment options for relapsed or refractory CLL are limited and are often accompanied by treatment-induced immuno-and myelosuppression.
1,2 Current purine analog-based regimens are associated with long-term T-cell depletion and increased risk of opportunistic infections. [1] [2] [3] Therefore, identifying alternate treatment options without accompanying hematologic toxicities has clinical relevance.
CLL cells can produce tumor necrosis factor (TNF), a cytokine that can improve viability and promote proliferation of CLL cells in vitro. 4, 5 TNF is likely a clinically relevant target in CLL, given that elevated plasma TNF levels are correlated with poor prognosis. 6 These observations have led to the hypothesis that blocking TNF in CLL patients would be efficacious.
In this study, we assessed the effect of the purine nucleoside analog LMP-420 (2-amino-6-chloro-9-[5(dihydroxyboryl)-pentyl] purine 7 on CLL cells freshly isolated from patients. LMP-420 is a novel anti-inflammatory agent that impairs peripheral blood mononuclear cell (PBMC) production of TNF without impairing PBMC viability. 8 Clinical trials of etanercept, a soluble chimeric TNF receptor that inhibits TNF-cell interactions, have thus far shown limited efficacy in CLL. 9, 10 However, LMP-420 acts through different mechanisms, both inhibiting TNF synthesis at the transcriptional level and altering expression of additional inflammatory mediators and cell surface molecules. 8 On the basis of the anti-apoptotic and pro-proliferative effects of TNF on CLL cells, we hypothesized that LMP-420 would be cytotoxic to CLL cells and have therapeutic potential for this disease.
Materials and methods

Cells
CLL patients from the Duke University and Durham VA Medical Centers were enrolled in Institutional Review Board-approved research protocols to collect clinical data and peripheral blood. Purification of CLL cells and determination of prognostic markers were performed as described previously. 11 Poor risk cytogenetic subgroups were 17p13 deletion or 11q22 deletion, while favorable cytogenetic subgroups were normal, 13q14 deletion or trisomy 12.
12 For toxicity studies, normal volunteers were enrolled in an Institutional Review Board-approved protocol for blood collection. PBMCs were isolated over HISTOPAQUE-1077 (Sigma-Aldrich, St Louis, MO, USA). Cells were cultured at 37 1C with 5% CO 2 in either Hybridoma Serum Free Medium with 10% fetal bovine serum or RPMI 1640 medium (Sigma-Aldrich) supplemented with 5% heat-inactivated human AB serum (Sigma-Aldrich), 50 units/ml penicillin, 50 mg/ml streptomycin, 2 mM L-glutamine, 25 mM HEPES, 100 mM minimum essential medium non-essential amino acids and 1 mM sodium pyruvate (GIBCO/Invitrogen, Carlsbad, CA, USA). CLL cell sensitivity to LMP-420 was not affected by media. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay CLL cells were incubated for 72 h with serial dilutions of LMP-420, fludarabine and/or recombinant TNF (R&D Systems, Minneapolis, MN, USA). CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) MTS reagent was added and plates were incubated for 4 h before measuring absorbance 490 nM in a Thermomax microplate reader (Molecular Devices, Sunnyvale, CA, USA). Fractional cytotoxicity and the concentration effective at killing 50% of CLL cells (ED50) was calculated as performed previously. 13 For purposes of statistical analyses, ED50 values outside the tested dose range were set to either the lowest or highest concentration tested.
Apoptosis assays
CLL cells cultured with vehicle control or drug for 24, 48 or 72 h of incubation were analyzed for apoptosis. Cells were analyzed for annexin V-phycoerythrin and 7-Aminoactinomycin D staining by the Guava EasyCyte Plus system (Millipore, Billerica, MA, USA). To facilitate comparison of samples with different levels of spontaneous apoptosis, drug-specific apoptosis is reported. Drug-specific apoptosis was calculated as 100% (drug-induced apoptosis-spontaneous apoptosis)/(100-spontaneous apoptosis).
14 Activation of caspases 3 and 7 was measured by Caspase-Glo 3/7 Assay, according to the manufacturer's protocol (Promega CLL cells were cultured with 1 mM CpG-oligodeoxynucleotide DSP30 15 (Midland Certified Reagent Company, Midland, TX, USA) and 100 units/ml interleukin-2 (R&D Systems) in the presence or absence of drug for 96 h, and then were incubated with 1 mCi per well [methyl-
3 H]-thymidine (specific activity 6.7 Ci/mmol, PerkinElmer, Waltham, MA, USA) for 14-18 h before harvest onto glass-fiber filters.
[3H]-thymidine incorporation was measured as counts per minute using a Tri-Carb 2100 timed-resolved liquid scintillation counter (PerkinElmer). PBMCs were stimulated with 10 mg/ml Phytohemagglutinin-P (Sigma-Aldrich), 5 mg/ml concanavalin A (Sigma-Aldrich), 2 mg/ ml pokeweed mitogen (Sigma-Aldrich), 25 ng/ml muromonab-CD3 (a-CD3, Ortho Pharmaceuticals, Raritan, NJ, USA) or 50 ng/ml phorbol myristate acetate (Sigma-Aldrich) plus 1 mg/ml ionomycin (Sigma-Aldrich) for 96 h. Proliferation is reported as percentage of control. Gene expression experiments and analysis CLL cells cultured with or without 2 mM LMP-420 for 24 h were washed and stored at À80 1C. Total RNA was extracted using Qiashredder and RNeasy Mini columns (Qiagen, Valencia, CA, USA), transcribed in vitro, then hybridized to U133Plus 2.0 GeneChips (Affymetrix, Santa Clara, CA, USA) according to manufacturer's instructions. All analyses were performed in a minimal information about a microarray experiment compliant manner. Genomic data are archived in the Gene Expression Omnibus (no. GSE20211). After processing with the Robust Multi-Array Average algorithm and batch normalization using ComBat, 16 significant differences in probe expression were determined using the Wilcoxon signed-rank test (Po0.001) and Bangamini-Hochberg false discovery rate (o0.05). 
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Results
CLL patient characteristics
Characteristics of CLL samples used are outlined in Table 1 . The majority of patients in the study had favorable prognostic indicators. Samples obtained from patients with poor prognostic markers include unmutated IgV H (27%), high CD38 expression (16%), poor risk interphase cytogenetics (11%) and short lymphocyte doubling time (9%, o1 year).
LMP-420 cytotoxicity for CLL cells
The capacity of LMP-420 to induce cytotoxicity in CLL cells was assessed using the MTS assay. The mean ED50 of LMP-420 for CLL cytotoxicity (n ¼ 35) was 245 nM (Figure 1a) . ED50 values ranged from o30 nM to 45 mM for individual patient samples (Figure 1b) .
LMP-420 induction of time-and dose-dependent apoptosis of CLL cells
In 43 CLL samples, LMP-420-induced statistically significant apoptosis in a time-dependent manner (Po0.0001). Incubation with 5000 nM LMP-420 at 24, 48 and 72 h resulted in median drug-specific apoptosis of 15, 28 and 32%, respectively (Figure 2a) . LMP-420 caused dose-dependent apoptosis in 50 CLL samples incubated with 50, 500 or 5000 nM LMP-420 for 72 h (Figure 2b, Po0.0001) . The 5000 nM dose of LMP-420-induced apoptosis in 98% of samples. Staining indicative of primary necrosis (7-Aminoactinomycin D-positive, annexin-Vnegative) was negligible in all samples (o2%). The time-and dose-dependent apoptotic effect of LMP-420 was confirmed by measurement of caspase activity (Supplementary Figure 1 , n ¼ 30, Po0.0001) and assessment of Mcl-1, Bcl-xL and Bcl-2 levels at 72 h. Cells incubated with 500 nM LMP-420 showed median decreases in Mcl-1, Bcl-xL and Bcl-2 expression of 29% (n ¼ 8, Po0.01), 41% (n ¼ 6, Po0.05) and 22% (n ¼ 8, P ¼ 0.06), respectively. Bax/Bcl-2 ratio was not affected.
To assess the extent to which CLL cells had undergone previous apoptosis and lysis ('secondary necrosis' 19 ), we quantified nucleosomes in the cell culture supernatant and in cell lysate at 72 h (Figure 2c) . Nucleosomes in the lysate indicate intact cells undergoing apoptosis, whereas nucleosomes in the supernatant correspond to cells that have released their contents by secondary necrosis. Nucleosome enrichment (n ¼ 5) was consistent with mean cytotoxicity measured by MTS assay (850 nM) rather than the mean 50% apoptosis measured by annexin V staining (5000 nM). Thus, LMP-420 is cytotoxic to CLL by cumulative apoptosis over time.
LMP-420 cytotoxicity for CLL cells from patients in poor prognostic groups
Cytotoxicity and level of drug-specific apoptosis observed with LMP-420 treatment did not correlate with Rai stage, previous treatment or cell surface expression of Zap70 or CD38. However, unmutated IgV H status was associated with significantly greater LMP-420-induced apoptosis than mutated IgV H status (Po0.01). Median percent apoptosis after 72-h incubation with 5000 nM LMP-420 was 34% for the mutated IgV H subgroup (n ¼ 30) and 59% for the unmutated IgV H subgroup (n ¼ 10). Apoptosis induced by 5000 nM LMP-420 ranged from 13 to 58% in samples with unfavorable cytogenetics. There was no 
LMP-420 inhibition of CLL cell proliferation
To determine if LMP-420 treatment inhibits proliferation of leukemic cells, CLL cells were stimulated to divide in vitro. 15, 20 Incubation with LMP-420 for 2 h before stimulation suppressed proliferation in a dose-dependent manner (Figure 2d ).
LMP-420 potentiation of the cytotoxic activity of fludarabine against CLL cells LMP-420 was evaluated to determine if it could potentiate the anti-CLL activity of fludarabine in vitro. LMP-420 was used at two concentrations, 62 and 250 nM. In a representative CLL sample, the addition of low nanomolar concentrations of LMP-420 to fludarabine increased cytotoxicity compared with fludarabine alone (Figure 3a) . In a series of 21 patient samples, both concentrations of LMP-420 resulted in significantly lower fludarabine concentrations required to achieve 50% cytotoxicity (Figure 3b , P ¼ 0.0007 and Po0.0001 for 62 and 250 nM, respectively).
Modulation of immune and nuclear factor (NF)-kB pathways by LMP-420 in CLL cells
Incubation of CLL cells with LMP-420 in combination with recombinant human TNF did not abrogate LMP-420 cytotoxicity (n ¼ 9, MTS assay) or apoptosis (n ¼ 4, annexin V assay).
Thus, LMP-420 toxicity to CLL cells is not likely due to suppression of an autocrine TNF loop. Gene expression profiling on CLL cells (n ¼ 13) after 24-h incubation with LMP-420 or media alone revealed other potential targets of LMP-420. Expression of 763 gene probes was increased, and expression of 633 gene probes was suppressed by treatment with 2 mM LMP-420 (Figure 4) . Among the downregulated genes, significant enrichment occurred in GO terms relating to immune responses ('Immune GO terms,' Figure 4) , as well as suppression of genes involved in the NF-kB pathway ('NF-kB GO terms', Figure 4) . Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed significant representation of the toll-like receptor signaling pathway and cytokine-cytokine receptor interactions. LMP-420 treatment was significantly associated with upregulation of genes enriched in the GO terms relating to metabolism and regulation of the NF-kB pathway. There was a significant reduction in the TNF and interferon-a pathway signature predictions for the LMP-420-treated cells compared with control cells (P ¼ 0.027 and 0.003, respectively). Decreased RNA expression of CD40 after treatment with LMP-420 was confirmed by measuring CD40 surface protein. CD40 protein expression on CLL cells from eight patients decreased by 12.4% at 24 and 33.7% at 72 h after treatment with 500 nM LMP-420 (P ¼ 0.008 for both time points).
Relative lack of LMP-420 cytotoxicity for normal PBMCs and hematopoietic precursor cells
Mean ED50 of LMP-420 on normal PBMCs was 4512 mM, whereas mean ED50 on CLL cells was 245 nM. Thus, the Figure 4 Gene expression profiling of CLL cells treated with LMP-420. CLL cell treatment with 2 mM LMP-420 resulted in 1396 differentially expressed gene probes relative to untreated control (left heatmap; red color represents upregulated genes and green color represents downregulated genes). Among these, Immune and NF-kB pathway GO terms were significantly represented (right heatmap, differentially expressed genes listed to the right).
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YM Mowery et al therapeutic index (PBMC ED50/CLL ED50) is 42000. In contrast, the therapeutic index for various chemotherapeutics currently used in CLL treatment is below 30 ( Table 2) . Although LMP-420 potentiates the cytotoxicity of fludarabine on CLL cells, it does not potentiate toxicity to normal PBMCs (Supplementary Figure 2) . LMP-420 does not induce significant apoptosis in normal B and T lymphocytes at concentrations up to 90 mM (P40.05, Figures 5a and b) . By contrast, treatment with 0.4 mM fludarabine caused significant apoptosis in both B and T cells (Po0.01 and Po0.05, respectively). Thus, LMP-420 is not toxic to normal B and T cells at doses well above its therapeutic dose range. LMP-420 inhibited proliferation of stimulated PBMCs, with IC50 values 100-to 250-fold higher than the mean ED50 of LMP-420 in CLL cells (Supplementary Table 1 ). In contrast, conventional chemotherapy agents inhibited proliferation of stimulated PBMCs no 415-fold above the ED50 of those agents in CLL cells. In addition, IC50s of LMP-420 for inhibiting erythroid and myeloid colony formation were 10 and 25 mM, respectively, while IC50s for fludarabine were 5 and 1 mM. Thus, in comparison with conventional chemotherapy, LMP-420 has minimal effect on proliferation and hematopoietic cell development.
Discussion
In this study, we show that LMP-420 has potent cytotoxic and anti-proliferative effects on primary CLL cells in vitro. LMP-420 resulted in loss of viability through time-and dose-dependent apoptosis. LMP-420 had neither the immuno-nor the myelosuppressive properties of fludarabine, but still potentiated the cytotoxic effects of this agent on CLL cells. Furthermore, this agent-induced cytotoxicity in samples with a broad range of clinical characteristics. Unlike conventional chemotherapy, LMP-420 was specific for CLL cells over normal hematopoetic cells. LMP-420-induced cytotoxicity and inhibited proliferation in CLL cells but not normal PBMCs, even at concentrations well above the mean ED50 for CLL cells. In contrast, fludarabineinduced apoptosis in normal lymphocytes and suppressed proliferation of normal PBMCs at concentrations toxic to CLL cells. Our data suggest that LMP-420 may be an effective, lowtoxicity treatment for CLL, either alone or in combination.
LMP-420 induces CLL cell-specific cytotoxicity through apoptotic mechanisms. This may be linked to alteration of cytokine milieu and modulation of cell surface receptors involved in interactions with supporting cells in the microenvironment. LMP-420 potently inhibits macrophage and lymphocyte production of TNF and interferon-g, cytokines known to be important in CLL cell viability. 5, 8, [21] [22] [23] LMP-420 also significantly decreases CLL cell expression of CD40, a receptor that improves CLL survival and induces proliferation through its interaction with CD40 ligand in the microenvironment. 24, 25 CD40 downregulation could affect cell survival in culture by decreasing interactions with CD40 ligand-expressing CLL cells 26 or the small percentage of T cells potentially remaining after purification.
As the percentage of CLL cells proliferating in vivo correlates with disease aggressiveness, 27 we studied the effect of LMP-420 on in vitro CLL cell proliferation. We speculate that in vitro stimulated proliferation may reflect the in vivo proliferative compartment, because higher proportions of proliferating CLL cells in vivo and proliferative response to DSP30 in vitro are associated with progressive disease. 28 LMP-420 significantly inhibited CLL cell proliferation at concentrations below those affecting stimulated proliferation of normal PBMCs.
We initially hypothesized that LMP-420 might be toxic to CLL cells through inhibition of autocrine TNF production. However, our results indicate that the mechanism of action is more complex, with gene expression profiling suggesting it involves the inhibition of NF-kB, toll-like receptor signaling pathways The CLL ED50 value for LMP-420 is the mean value from the MTS experiments described above. The values for other drugs are the minimum values from the range reported in the literature or the mean ED50 observed in MTS assays performed on CLL samples in this study, whichever is lower. [36] [37] [38] [39] [40] [41] The PBMC ED50 values reported are mean values from experiments performed on PBMCs isolated from healthy blood donors (n ¼ 3-6). LMP-420-induced cytotoxicity in CLL YM Mowery et al and cytokine-cytokine receptor interactions. For example, LMP-420-induced expression of RhoH and SQSTM1, two suppressors of the NF-kB pathway. 29, 30 Similarly, LMP-420 suppressed expression of CD40, TICAM2 (TRAM) and TNFSF10 (TRAIL), which activate the NF-kB pathway. [31] [32] [33] These results support previous findings of the therapeutic potential of inhibiting the NF-kB pathway in CLL cells. 34, 35 In conclusion, this study shows that LMP-420 is cytotoxic to primary CLL cells from patients with low-or high-risk prognostic factors. Furthermore, the drug potentiates the activity of fludarabine and shows a high degree of selectivity for leukemic B cells. LMP-420 also has the practical benefits of being inexpensive to synthesize, highly stable, well-tolerated in vivo and orally bioavailable. 7 Studies are ongoing to characterize the mechanism of action of LMP-420 further, with particular focus on its differential effects on CLL cells versus normal PBMCs. Given its favorable toxicity profile and efficacy both as a single agent and in combination with fludarabine, additional preclinical evaluation of LMP-420 for the treatment of CLL is warranted.
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